US Patent

US8829195 — Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

Method of Use · Assigned to Novartis AG · Expires 2035-10-29 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compounds that inhibit the activity of BCR-ABL1 and its mutants, which are used in the treatment of cancers.

USPTO Abstract

The present invention relates to compounds of formula (I): in which Y, Y1, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1374 — Scemblix
U-1374 — Scemblix
U-1374 — Scemblix

Patent Metadata

Patent number
US8829195
Jurisdiction
US
Classification
Method of Use
Expires
2035-10-29
Drug substance claim
Yes
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.